Clinical challenges in the management of isolated GH deficiency type IA in adulthood
Casteràs, Anna (Hospital Universitari Vall d'Hebron)
Kratzsch, Jürgen (University of Leipzig)
Ferrández, Ángel (Hospital Universitario Miguel Servet (Saragossa))
Zafón, Carles (Hospital Universitari Vall d'Hebron)
Carrascosa Lezcano, Antonio 1949- (Hospital Universitari Vall d'Hebron)
Mesa Manteca, Jordi (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Date:	2014
Abstract:	Isolated GH deficiency type IA (IGHDIA) is an infrequent cause of severe congenital GHD, often managed by pediatric endocrinologists, and hence few cases in adulthood have been reported. Herein, we describe the clinical status of a 56-year-old male with IGHDIA due to a 6. 7 kb deletion in GH1 gene that encodes GH, located on chromosome 17. We also describe phenotypic and biochemical parameters, as well as characterization of anti-GH antibodies after a new attempt made to treat with GH. The height of the adult patient was 123 cm. He presented with type 2 diabetes mellitus, dyslipidemia, osteoporosis, and low physical and psychological performance, compatible with GHD symptomatology. Anti-GH antibodies in high titers and with binding activity (>101 IU/ml) were found 50 years after exposure to exogenous GH, and their levels increased significantly (>200 U/ml) after a 3-month course of 0. 2 mg/day recombinant human GH (rhGH) treatment. Higher doses of rhGH (1 mg daily) did not overcome the blockade, and no change in undetectable IGF1 levels was observed (<25 ng/ml). IGHDIA patients need lifelong medical surveillance, focusing mainly on metabolic disturbances, bone status, cardiovascular disease, and psychological support. Multifactorial conventional therapy focusing on each issue is recommended, as anti-GH antibodies may inactivate specific treatment with exogenous GH. After consideration of potential adverse effects, rhIGF1 treatment, even theoretically indicated, has not been considered in our patient yet. Learning points: Severe isolated GHD may be caused by mutations in GH1 gene, mainly a 6. 7 kb deletion. Appearance of neutralizing anti-GH antibodies upon recombinant GH treatment is a characteristic feature of IGHDIA. Recombinant human IGF1 treatment has been tested in children with IGHDIA with variable results in height and secondary adverse effects, but any occurrence in adult patients has not been reported yet. Metabolic disturbances (diabetes and hyperlipidemia) and osteoporosis should be monitored and properly treated to minimize cardiovascular disease and fracture risk. Cerebral magnetic resonance imaging should be repeated in adulthood to detect morphological abnormalities that may have developed with time, as well as pituitary hormones periodically assessed.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Endocrinology, Diabetes & Metabolism Case Reports, Vol. 2014 (february 2014) , ISSN 2052-0573

DOI: 10.1530/EDM-13-0057
PMID: 24683479

6 p, 158.0 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles